Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

WuXi Vaccines Achieves GMP Release for First Drug Substance Facility in China

Friday, July 28, 2023

WuXi Vaccines announced the successful GMP (Good Manufacturing Practise) release for its first drug substance (DS) manufacturing facility in Suzhou, China. 

With the GMP release, the facility is now authorised to produce drug substances, and production has already commenced. The use of single-use bioreactors up to 1000L enhances both the efficiency and quality of drug substance manufacturing, enabling larger-scale production of vaccines.

The site is also expanding its manufacturing capabilities by developing drug substance capacity based on microbial and viral platforms up to BSL2. This will allow them to diversify their portfolio of vaccines and respond to different disease targets.

Additionally, it also plans to build a fill & finish facility. Fill & finish is the final step in the vaccine manufacturing process, where the vaccine product is put into its final containers, such as vials or syringes. This facility will offer various processes, including liquid, lyophilisation (freeze-drying), suspension, and emulsion, enabling the production of different types of vaccines.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024